Enabling a better product for cancer patients to improve quality of life

We are dedicated to rapidly advancing our key pipeline assets through clinical evaluation with initial focus on metastatic castration-resistant prostate cancer and other solid tumors.


Metastatic Castration-Resistant Prostate Cancer (mCRPC)

mCRPC is an advanced form of prostate cancer and the fourth most common cause of cancer death overall. mCRPC is resistant to surgical treatment or androgen deprivation therapy, an antihormone therapy used to prevent the growth of prostate cancer cells. IV Docetaxel is currently the first-line treatment in this indication in chemotherapy naïve patients. Modra is currently conducting a Phase II clinical trial of Modra006/r in patients with mCRPC.
The following clinical trials of ModraDoc006/r are currently ongoing.


Phase I results with ModraDoc006/r published in the European Journal of Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more


Meet us at one of the following events:      
Read more